Incyte (INCY) Stock Price, News & Analysis

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.

15 analysts have issued twelve-month price targets for Incyte's shares. Their INCY share price targets range from $64.00 to $93.00. On average, they anticipate the company's share price to reach $76.07 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.

Incyte's stock was trading at $62.79 at the start of the year. Since then, INCY shares have decreased by 14.5% and is now trading at $53.71.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our INCY earnings forecast.

Incyte will be holding an earnings conference call on Tuesday, April 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745743".

Incyte Co. (NASDAQ:INCY) issued its quarterly earnings results on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by $0.09. The biopharmaceutical company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Incyte had a trailing twelve-month return on equity of 12.56% and a net margin of 16.17%. The company's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.44 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Virtus LifeSci Biotech Products ETF (BBP), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ASYMshares ASYMmetric S&P 500 ETF (ASPY), Strategas Global Policy Opportunities ETF (SAGP) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.69%), IMC Chicago LLC (0.00%), Fulton Bank N.A. (0.01%), First Hawaiian Bank (0.01%), Alaska Permanent Fund Corp (0.01%) and Davis Investment Partners LLC (0.01%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.